Established by a team of Stanford alumni, Avails Medical, Inc is structured around fighting the major global health threat of antibiotic resistance. The developed technology platform directly adddresses the need radically to reduce the time required to obtain the reliable antibiotic susceptibility data that enables accurate therapy decisions. Avails' electronic biosensor technology is designed to improve accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps. The firm's digital technology is designed to provide accurate, rapid detection of infections in any bodily fluid while also indicating - in real-time - which drugs are most effective at the point-of-prescription. For decades, lab technicians have detected infections primarily through crude, time-consuming, error-ridden techniques of dipsticks and specimen sampling, leaving physicians to guess which antibiotic might be effective since reliable results can take days to develop. Avails' electronic biosensor technology improves accuracy in detecting infections and provides critical, timely information regarding antibiotic sensitivity and resistance. Avails' cost-effective platform will transform the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-care, reducing time-to-treatment from days to minutes.
